Search hospitals > West Virginia > Charleston
West Virginia University Charleston Division
Claim this profileCharleston, West Virginia 25304
Global Leader in Cancer
Global Leader in Leukemia
Conducts research for Tumors
Conducts research for Adenocarcinoma
Conducts research for Breast Cancer
172 reported clinical trials
5 medical researchers
Summary
West Virginia University Charleston Division is a medical facility located in Charleston, West Virginia. This center is recognized for care of Cancer, Leukemia, Tumors, Adenocarcinoma, Breast Cancer and other specialties. West Virginia University Charleston Division is involved with conducting 172 clinical trials across 379 conditions. There are 5 research doctors associated with this hospital, such as Steven J. Jubelirer, Ahmed A. Khalid, Ashley E. Meyer, and Mohamad H. Badawi.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
Stage I
2Leukemia
Global LeaderCD5 positive
Stage II
Stage IV
Top PIs
Steven J. JubelirerWest Virginia University Charleston Division4 years of reported clinical research
Expert in Cancer
Studies Lung Cancer
30 reported clinical trials
78 drugs studied
Ahmed A. KhalidWest Virginia University Charleston Division1 year of reported clinical research
Expert in Cancer
Studies Lung Cancer
30 reported clinical trials
78 drugs studied
Ashley E. MeyerWest Virginia University Healthcare4 years of reported clinical research
Studies Leukemia
Studies Tumors
23 reported clinical trials
62 drugs studied
Mohamad H. BadawiWest Virginia University Charleston Division4 years of reported clinical research
Studies Cancer
Studies Tumors
17 reported clinical trials
54 drugs studied
Clinical Trials running at West Virginia University Charleston Division
Breast Cancer
Lung Cancer
Non-Small Cell Lung Cancer
Cancer
Prostate Cancer
Diffuse Large B-Cell Lymphoma
Squamous Cell Carcinoma
Rhabdomyosarcoma
Follicular Lymphoma
Ovarian Cancer
Durvalumab + Chemotherapy
for Breast Cancer
This phase III trial compares the addition of an immunotherapy drug (durvalumab) to usual chemotherapy versus usual chemotherapy alone in treating patients with MammaPrint Ultrahigh (MP2) stage II-III hormone receptor positive, HER2 negative breast cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as paclitaxel, doxorubicin, and cyclophosphamide work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. There is some evidence from previous clinical trials that people who have a MammaPrint Ultrahigh Risk result may be more likely to respond to chemotherapy and immunotherapy. Adding durvalumab to usual chemotherapy may be able to prevent the cancer from returning for patients with MP2 stage II-III hormone receptor positive, HER2 negative breast cancer.
Recruiting2 awards Phase 340 criteria
T-DM1 + Tucatinib
for Breast Cancer
This study is evaluating whether a combination of two drugs may help prevent breast cancer from coming back.
Recruiting1 award Phase 313 criteria
Chemotherapy Reduction After Surgery
for Breast Cancer
This study is evaluating whether a combination of drugs may help treat breast cancer.
Recruiting1 award Phase 227 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at West Virginia University Charleston Division?
West Virginia University Charleston Division is a medical facility located in Charleston, West Virginia. This center is recognized for care of Cancer, Leukemia, Tumors, Adenocarcinoma, Breast Cancer and other specialties. West Virginia University Charleston Division is involved with conducting 172 clinical trials across 379 conditions. There are 5 research doctors associated with this hospital, such as Steven J. Jubelirer, Ahmed A. Khalid, Ashley E. Meyer, and Mohamad H. Badawi.